Clinical trials · Maryland
Cancer clinical trials in Maryland
We’re tracking 707 recruiting cancer studies with a site in Maryland — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Silver Spring, MarylandAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Silver Spring, MarylandAges 18 years+ - NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Columbia, MarylandAges 18 years+ - NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Rockville, MarylandAges 18 years+ - NCT06904066RecruitingPhase 1
Personalized T cell therapy for blood cancers
This trial tests a treatment that takes your own immune cells, modifies them to attack cancer cells, and gives them back to you. It is for people with certain blood cancers who have specific gene changes.
Bethesda, MarylandAges 18–120 - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Baltimore, MarylandAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Baltimore, MarylandAges 18 years+ - NCT05691517RecruitingPhase 1
Test drug CBX-12 in advanced cancers and monitor your response
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Bethesda, MarylandAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Silver Spring, MarylandAges 18 years+ - NCT06712316RecruitingPhase 2/Phase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
Frederick, MarylandAges 18 years+ - NCT05604560RecruitingPhase 2
New drug combo before surgery for resectable pancreatic cancer
This trial tests two drugs, tislelizumab and SX-682, given before surgery for people with pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Baltimore, MarylandAges 18 years+ - NCT06084416RecruitingPhase 1
Pill study for advanced ovarian cancer that resists chemo
This trial tests an experimental drug called sovilnesib (taken as a pill) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemo. The goal is to see if this drug can shrink or slow the cancer.
Baltimore, MarylandAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Silver Spring, MarylandAges 18 years+ - NCT07851025RecruitingPhase 3
Maintenance therapy for advanced ovarian cancer
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
Baltimore, MarylandAges 18 years+ - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Baltimore, MarylandAges 18 years+ - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Baltimore, MarylandAges 18 years+ - NCT07543757Recruiting
Blood test to help decide if a prostate biopsy is needed
This study tests a new blood test (Proclarix) that may help doctors decide if a prostate biopsy is needed. It is for men with a slightly elevated PSA who are already considering a biopsy.
Hanover, MarylandAges 40–75 - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Baltimore, MarylandAges 18 years+ - NCT07550517RecruitingPhase 2
Radiation plus experimental nuclear medicine for high-risk prostate cancer
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
Baltimore, MarylandAges 18 years+ - NCT07512154Recruiting
Precision Brain Tumor Radiotherapy Using Advanced MRI
This study tests a new way to plan and deliver radiation therapy for glioblastoma (an aggressive brain tumor) using special MRI scans to target cancer cells more precisely. The goal is to improve treatment effectiveness while reducing harm to healthy brain tissue.
Baltimore, MarylandAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Baltimore, MarylandAges 18 years+ - NCT07419295RecruitingPhase 3
Testing a new drug for advanced bladder cancer
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
Baltimore, MarylandAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT07415681RecruitingPhase 2
Photon vs. Proton Radiation for New Gynecologic Cancers
This trial compares two types of radiation (standard photon vs. newer proton) for people with newly diagnosed endometrial or cervical cancer. It aims to see if proton therapy reduces side effects while controlling the cancer just as well.
Baltimore, MarylandAges 18 years+
Cancer trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting cancer studies listed above.
- Johns Hopkins University · 6 studies
- Research Site · 3 studies
- Maryland Oncology Hematology, P.A. · 2 studies
- National Institutes of Health Clinical Center · 2 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2 studies
- Baltimore Washington Medical Center- Tate Cancer Center
- Central Maryland Radiation Oncology
- Chesapeake Urology Associates
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Maryland?
- Yes. We're currently tracking 707 recruiting cancer studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.